- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com
© 2026 WuXi AppTec. All Rights Reserved.Privacy Policy
Breakthroughs in medicine don’t happen in isolation – they are driven by a shared commitment to innovation and collaboration for patients. In this fresh edition of WXPRESS, we hear from the distinguished leaders who truly embody this spirit: Dr. Laurie Glimcher, President and CEO Emerita of Dana-Farber Cancer Institute; Dr. Paulo Fontoura, Chief Medical Officer of Xaira Therapeutics; and Dr. Michael Altorfer, CEO of the Swiss Biotech Association. From the future of cancer treatment to AI-driven drug discovery and global collaboration, their collective perspectives remind us why what we do matters so much to patients.
That same spirit drives the fight against rare diseases. In recognition of Rare Disease Day on February 28, we highlight in this edition those leading the charge: Dr. Stanley T. Crooke, Founder, CEO and Chairman of the Board at n-Lorem Foundation; Prof. Christoph Klein, Professor and Chair, Dr. von Hauner Children's Hospital at Ludwig Maximilians University; Dr. Annette Bakker, CEO of the Children's Tumor Foundation; and Calaneet Balas, President and CEO of The ALS Association. Their tireless efforts are transforming lives and bringing hope to patients who need it most.
This spirit is also at the heart of the recent 13th WuXi Global Forum, where thousands of senior leaders and innovators gathered to exchange ideas and push the boundaries of new medicine. It’s also why we joined the Pharmaceutical Supply Chain Initiative (PSCI) a few weeks ago as a Supplier Partner, further reinforcing our steadfast commitment to responsible global practices. The spirit of collaboration and innovation has guided WuXi AppTec for the past 24 years, and it’s our privilege to support innovators worldwide who drive meaningful progress for patients every day.
At the private speakers' luncheon during WuXi Global Forum 2025, Dr. Laurie Glimcher, President and CEO Emerita of Dana-Farber Cancer Institute, delivered a thought-provoking talk on the progress, challenges, and future directions of cancer treatment. Her insights offered a powerful glimpse into where we stand in the fight against one of the most complex and devastating diseases of our time.
In 2024, Xaira Therapeutics was launched with a groundbreaking $1B capital raise. The company's generative AI capabilities span from developing fundamental computational methods to applying these techniques in biological discovery, molecule design, and clinical development. We recently sat down with Dr. Paulo Fontoura, an industry veteran and the newly appointed Chief Medical Officer of Xaira, to discuss what gets him excited at Xaira, and his vision for the future of drug discovery and development.
Switzerland has consistently contributed to today’s global pharma and biotech industries, serving as a beacon of collaboration, innovation and excellence. As Swiss Biotech Day approaches this May, Michael Altorfer, CEO of the Swiss Biotech Association, shares his insights on how the country's robust infrastructure, collaborative spirit, and rich history in research continue to drive global progress in biotechnology.
